HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Mefloquine (Lariam)

A phospholipid-interacting antimalarial drug (ANTIMALARIALS). It is very effective against PLASMODIUM FALCIPARUM with very few side effects.

Also Known As:

Lariam; Hoffmann-La Roche Brand of Mefloquine Hydrochloride; Mefloquine Hydrochloride; Mephloquine; Ro-21-5998-001; Roche Brand of Mefloquine Hydrochloride; WR-142,490; WR-177,602; Hoffmann La Roche Brand of Mefloquine Hydrochloride; Ro 21 5998 001; Ro215998001; WR 142,490; WR 177,602; WR142,490; WR177,602; 4-Quinolinemethanol, alpha-2-piperidinyl-2,8-bis(trifluoromethyl)-, (R*,S*)-(+-)-

Networked: 973 relevant articles (172 outcomes, 170 trials/studies)

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 60
- 2-Ring Heterocyclic Compounds
  - Quinolines: 92
    - Mefloquine: 973

Experts

1.	White, Nicholas J: 22 articles (04/2014 - 03/2002)
2.	Singhasivanon, Pratap: 13 articles (01/2012 - 01/2003)
3.	Looareesuwan, S: 12 articles (04/2011 - 06/2000)
4.	Schlagenhauf, Patricia: 11 articles (09/2015 - 05/2007)
5.	Na-Bangchang, Kesara: 11 articles (08/2014 - 01/2005)
6.	McGready, Rose: 11 articles (04/2014 - 12/2002)
7.	Nosten, François: 11 articles (03/2013 - 12/2002)
8.	Lim, Pharath: 11 articles (01/2013 - 01/2005)
9.	Looareesuwan, Sornchai: 11 articles (07/2010 - 03/2002)
10.	Wongsrichanalai, Chansuda: 10 articles (05/2010 - 08/2003)

Related Diseases

1.	Falciparum Malaria (Plasmodium falciparum Malaria) 09/01/1996 - "falciparum malaria in Gabon, while mefloquine proved to be highly effective for this purpose." 01/01/1987 - "The radical cure rate of nearly 98% and high tolerance indicate that mefloquine can be used effectively and safely for the treatment of children aged 5-12 years who are suffering from uncomplicated falciparum malaria." 04/01/1987 - "Based on the elimination of parasitaemia, the plasma mefloquine concentrations are adequate for therapy of uncomplicated falciparum malaria although the relationship between plasma concentrations and therapeutic efficacy of mefloquine requires further study." 10/01/2003 - "[Mefloquine treatment in infants and children with Plasmodium falciparum malaria: an efficient and well tolerated treatment]." 01/01/1994 - "Falciparum malaria in eastern Thailand: a randomized trial of the efficacy of a single dose of mefloquine."
2.	Malaria 11/29/1997 - " One placebo-controlled trial directly examined malaria incidence and showed mefloquine to be highly effective in preventing malaria in an area of drug resistance. " 11/29/1997 - "One trial showed mefloquine to be effective in preventing malaria, but withdrawal rates, presumably from side effects, were high across most studies. " 11/29/1997 - "One placebo controlled trial examined malaria incidence directly and showed mefloquine to be highly effective in preventing malaria in an area of drug resistance. " 10/21/2009 - "Two novel SF5 analogs of the antimalarial agent mefloquine were synthesized in 5 steps and 10-23% overall yields and found to have improved activity and selectivity against malaria parasites. " 05/01/1985 - "A clinical field trial was conducted to determine if mefloquine is effective in the treatment of malaria due to Plasmodium vivax. "
3.	Infection 06/01/1994 - "Combination regimens with mefloquine have proved highly effective against multi-drug resistant Plasmodium falciparum infections. " 03/01/1994 - "Mefloquine gave > or = 86% (95% confidence interval [CI], 59%-94%) protection against Plasmodium falciparum and complete protection against Plasmodium vivax infections. " 03/01/2013 - "Efficacy of mefloquine intermittent preventive treatment in pregnancy against Schistosoma haematobium infection in Gabon: a nested randomized controlled assessor-blinded clinical trial." 03/01/2013 - "Provided that further studies confirm these findings, the use of mefloquine may transform future IPTp programs into a 2-pronged intervention addressing 2 of the most virulent parasitic infections in pregnant women in sub-Saharan Africa. " 08/01/2015 - "Day 7 plasma PP concentrations and median 50% inhibitory concentrations (IC50) of PP were independent of treatment outcomes, in contrast to median mefloquine IC50, which were found to be lower for isolates from patients with recrudescent infections (18.7 versus 39.7 nM; P = 0.005). "
4.	Parasitemia 11/01/1999 - "Patients who received mefloquine monotherapy and cleared parasitemia in less than 48 hours had a significantly higher AUC(0-infinity) independent of any confounders, compared with patients with slower parasite clearance (geometric mean [95% CI], 50,373 ng/mL x day [46,121 to 55,017 ng/mL x day] versus 45,583 ng/mL x day [42,306 to 49,125 ng/mL x day]). " 05/01/2011 - "All members of the control cohort but none of the mefloquine cohort developed patent parasitemia. " 05/01/1993 - "Monkeys vaccinated with either SERA 1 and Freund's, SERA 1 and MF75.2, or MF75.2 alone and that had been challenged but did not develop a countable parasitemia were treated with a curative dose of mefloquine 100 days after parasite challenge and then rechallenged 40 days later. " 11/21/1992 - " Parasites did not clear from the blood of 2 patients in the mefloquine group, although there was a decrease in parasitemia. " 09/01/1990 - "The use of lariam leads to a more rapid (as compared to the standard treatment) elimination of parasitemia and complete eradication of the disease relapses. "
5.	Body Weight (Weight, Body) 09/01/2004 - "The relationship between body weight and tolerance to mefloquine prophylaxis in non-immune adults: results of a questionnaire-based study." 01/01/1992 - "A total of 47 nonimmune febrile patients from Pikine, Senegal, with greater than 1,000 Plasmodium falciparum asexual forms per microliter whole blood were given 12.5 mg per kg body weight of mefloquine in a single oral dose and were followed up daily until day 7 and also on day 14 of the study. " 01/01/1982 - "Different doses of mefloquine (20 and 30 mg/kg of body weight in children, and 750 and 1000 mg in adults) were tested in controlled clinical trials in 89 children and 60 adults who were semi-immune carriers of Plasmodium falciparum. " 01/01/2013 - "This case seems to be attributed to mefloquine resistance, however it is suggested that mefloquine dosage should be modulated by body weight, as is already indicated by some authorities. " 02/01/2011 - "Oral application of mefloquine (25 mg/kg of body weight administered twice a week for a period of 8 weeks) in E. "

Related Drugs and Biologics

1.	artesunate
2.	Chloroquine (Aralen)
3.	sulfadoxine-pyrimethamine (Fansidar)
4.	artemether
5.	Quinine (Quinson)
6.	halofantrine (Halfan)
7.	lumefantrine
8.	artemisinine (artemisinin)
9.	dihydroquinghaosu (dihydroartemisinin)
10.	Pyrimethamine (Daraprim)

Related Therapies and Procedures

1.	Chemoprevention
2.	Retreatment
3.	Drug Therapy (Chemotherapy)
4.	Aftercare (After-Treatment)
5.	Investigational Therapies (Experimental Therapy)